8-K: Serina Therapeutics Completes Merger with AgeX, Focuses on Clinical Trials
Merger Announcement
Serina Therapeutics has finalized its merger with AgeX Therapeutics, commencing trading under the ticker symbol SER and prioritizing the advancement of its lead drug candidate.
Summary
- Serina Therapeutics has completed its merger with AgeX Therapeutics, with the combined company now trading under the symbol SER.
- The merger was structured as a reverse recapitalization, with Serina being the accounting acquirer.
- Former Serina equity holders now own approximately 75% of the combined company, while former AgeX equity holders own approximately 25%.
- The company's lead drug candidate, SER-252 (POZ-apomorphine), is in preclinical studies, with an IND submission planned for 2025.
- The company expects to receive approximately $15 million from Juvenescence through the exercise of warrants, which is expected to fund operations through 2025.
Sentiment
Score: 6
Explanation: The document presents a mixed picture. The merger is a positive step, but the company's financial history and dependence on future funding raise concerns. The focus on clinical trials and the Pfizer partnership are positive, but the risks are significant.
Positives
- The merger provides Serina with access to public markets and additional capital.
- The company has a clear focus on advancing its lead drug candidate, SER-252, into clinical trials.
- The company has a non-exclusive license agreement with Pfizer, Inc. to use its POZ polymer technology for use in lipid nanoparticle drug delivery formulations.
- The company expects to receive approximately $15 million from Juvenescence through the exercise of warrants, which is expected to fund operations through 2025.
Negatives
- The company has a history of operating losses and negative cash flows.
- The company is dependent on raising additional capital to fund its operations.
- The company is subject to risks and uncertainties common to early-stage biotechnology companies.
Risks
- The company is subject to risks and uncertainties common to early-stage biotechnology companies, including technical risks, competition, and regulatory hurdles.
- The company's ability to obtain regulatory approvals for its product candidates is uncertain.
- The company's ability to raise additional capital is uncertain.
- The company's ability to successfully commercialize its product candidates is uncertain.
- The company's ability to remain listed on the NYSE American is not guaranteed.
- The company is dependent on the exercise of warrants by Juvenescence for a significant portion of its funding.
Future Outlook
Serina will focus on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), through pre-clinical studies towards the goal of an investigational new drug submission or IND to the Food and Drug Administration for the initiation of a Phase I clinical trial during the fourth quarter of 2024. The company expects to receive approximately $15 million from Juvenescence through the exercise of warrants, which is expected to fund operations through 2025.
Management Comments
- Serina Board Chair J. Milton Harris, Ph.D., stated, 'This merger is the culmination of years of work on the part of the Serina team and enables us to move our lead polyoxazoline-drug conjugate into clinical trials. We will endeavor to advance additional clinical candidates, further develop our LNP and ADC platforms, and look forward to presenting the Serina opportunity to a new investor audience.'
Industry Context
The merger positions Serina as a clinical-stage biotechnology company focused on neurological diseases and pain, leveraging its proprietary POZ platform. This is in line with the industry trend of developing novel drug delivery technologies to improve the efficacy and safety of existing and new therapeutics.
Comparison to Industry Standards
- The company's focus on a proprietary drug delivery platform (POZ) is similar to other biotech companies like Nektar Therapeutics, which also developed a PEGylation technology for drug delivery.
- The development of SER-252, a POZ-apomorphine conjugate for Parkinson's disease, is comparable to other companies developing novel therapies for Parkinson's, such as NeuroDerm, which is developing a subcutaneous apomorphine infusion therapy.
- The company's focus on LNP delivery technology is similar to other companies in the RNA therapeutics space, such as Moderna and BioNTech, which are using LNP technology for their mRNA vaccines and therapeutics.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Interim Chief Executive Officer | Joanne M. Hackett | Steven Ledger | March 26, 2024 | Merger completion |
| Interim Chief Financial Officer | NA | Andrea E. Park | March 26, 2024 | Merger completion |
| Chief Scientific Officer | NA | Randall Moreadith, M.D., Ph.D. | March 26, 2024 | Merger completion |
| Chief Operating Officer; Secretary | NA | Tacey Viegas, Ph.D. | March 26, 2024 | Merger completion |
| Class III Director | NA | Gregory M. Bailey, M.D. | March 26, 2024 | Merger completion |
| Class I Director | NA | Steven Mintz | March 26, 2024 | Merger completion |
| Class I Director | NA | Remy Gross | March 26, 2024 | Merger completion |
| Chairman of the Board and Class II Director | NA | J. Milton Harris, Ph.D. | March 26, 2024 | Merger completion |
| Class III Director | NA | Richard Marshall, M.D., Ph.D. | March 26, 2024 | Merger completion |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Policy | The company adopted a new outside director compensation policy, effective April 1, 2024, which includes annual retainers and equity awards. | April 1, 2024 | The new policy provides a framework for compensating non-employee directors and aligns their interests with those of the company. |
Legal Proceedings
- There are no material legal proceedings disclosed in the document.
Related Party Transactions
- The company has a convertible promissory note with AgeX, which was converted into equity as part of the merger.
- The company has a non-exclusive license agreement with Pfizer, Inc. to use its POZ polymer technology for use in lipid nanoparticle drug delivery formulations.
- The company expects to receive approximately $15 million from Juvenescence through the exercise of warrants.
Stakeholder Impact
- Shareholders of Serina and AgeX have been impacted by the merger, with former Serina shareholders owning approximately 75% of the combined company and former AgeX shareholders owning approximately 25%.
- Employees of both companies have been impacted by the merger, with some management changes and potential for future changes.
- Customers and partners of both companies may be impacted by the merger, with potential for new collaborations and product development opportunities.
- Creditors of both companies may be impacted by the merger, with changes in the capital structure and debt obligations.
Next Steps
- Complete preclinical studies for SER-252.
- Submit an IND application to the FDA for SER-252.
- Initiate a Phase I clinical trial for SER-252 in 2025.
- Advance other product candidates.
- Further develop the LNP and ADC platforms.
Key Dates
| Date | Description |
|---|---|
| August 29, 2023 | Date of the Merger Agreement between AgeX, Merger Sub, and Serina. |
| March 14, 2024 | AgeX implemented a 1 for 35.17 reverse stock split of its common stock. |
| March 18, 2024 | Warrant Dividend Record Date for AgeX common stock holders. |
| March 19, 2024 | AgeX issued post-merger warrants to holders of AgeX common stock. |
| March 26, 2024 | Date of completion of the merger between AgeX and Serina, with AgeX changing its name to Serina Therapeutics, Inc. |
| March 27, 2024 | Shares of Serina began trading on the NYSE American under the ticker symbol SER. |
| May 31, 2024 | At least one-third of the post-merger warrants held by Juvenescence are expected to be exercised. |
| November 30, 2024 | At least one-third of the post-merger warrants held by Juvenescence are expected to be exercised. |
| June 30, 2025 | At least one-third of the post-merger warrants held by Juvenescence are expected to be exercised. |
Keywords
Merger, Serina Therapeutics, AgeX Therapeutics, SER-252, POZ-apomorphine, Clinical Trials, Biotechnology, Neurological Diseases, Parkinson's Disease, Drug Development, IPO, Reverse Recapitalization, Juvenescence, LNP, ADC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.